News for CymaBay Therapeutics, Inc. (CBAY)

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its first quarter 2025 results of operations. ”œGilead had a strong start to the year driven by excellen

We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take a look at where Gilead Sciences, Inc.

The American quant hedge fund Renaissance Technologies is known for using statistical and mathematical tools to drive its investment programs.

We recently published a list of 15 Best NASDAQ Dividend Stocks To Buy. In this article, we are going to take a look at where Gilead Sciences, Inc.

Macroeconomic factors have weighed on US stocks in the final days of the year, with the broader market declining by over 1% in the past week.

Gilead Sciences' SWOT analysis: HIV leader faces oncology hurdles, seeks liver disease growth

Advancements and Projections in the Pharmaceutical Intermediates Market: Insights, Trends, Opportunities, and Recent Developments...

This week, once again, companies across the biotech sector continued to re-evaluate their pipelines and trim their workforces in a bid to conserve cash and extend their financial runway.

The week saw FDA reprimanding a pharma giant for making false and misleading claims about its non-small cell lung cancer drug and a developer of MDMA therapy for PTSD facing a major setback.

89bio Reports Second Quarter 2024 Financial Results and Corporate Updates

Gilead's adjusted EPS and revenue growth is currently expected to be 2.9%. Read why the market's lack of enthusiasm for GILD stock is understandable.

89bio enhances board with new director appointment

With volatility increasing in global stock markets, there is an ever-important need to include defensive stocks in an investor’s portfolio.

Gilead's Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary Cholangitis

Numerous drugs under development are projected to come to market later this year and next for Gilead. Read why I rate GILD stock a Buy.

Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis

Drug blockbusters facing key patent expirations and Big Pharma's surplus of cash suggest increased M&A volume in the coming year. Click here to read our picks.

Gilead Sciences will report its Q1 2024 earnings on Thursday, April 25. Check out whether GILD stock is a good buy ahead of Q1 earnings.

The rise in the number of people suffering from cirrhosis can be attributed to rapidly changing lifestyles such as an increase in alcohol consumption and...